Comparison of Poly (ADP-ribose) Polymerase Inhibitors (PARPis) as Maintenance Therapy for Platinum-Sensitive Ovarian Cancer: Systematic Review and Network Meta-Analysis

Comparison of Poly (ADP-ribose) Polymerase Inhibitors (PARPis) as Maintenance Therapy for Platinum-Sensitive Ovarian Cancer: Systematic Review and Network Meta-Analysis

Background: Three PARPis (olaparib, niraparib and rucaparib) are currently FDA-approved as maintenance therapy in newly diagnosed and recurrent ovarian cancer. However, thus far, no trial has compared the three approved PARPis in the overall population, in patients with <i>BRCA</i> mutat...

Full description

Bibliographic Details
Main Authors: Amos Stemmer, Inbal Shafran, Salomon M. Stemmer, Daliah Tsoref
Format: Article
Language:English
Published: MDPI AG 2020-10-01
Series:Cancers
Subjects:
adverse event
network meta-analysis
ovarian cancer
overall survival
poly (ADP-ribose) polymerase inhibitor
platinum-sensitive
Online Access:https://www.mdpi.com/2072-6694/12/10/3026

Internet

https://www.mdpi.com/2072-6694/12/10/3026

Similar Items